Cardiology Development Radiology 
Medical Xpress
NOVEMBER 29, 2022
Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10-year risk of death from a heart attack or stroke stemming from atherosclerotic cardiovascular disease. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).
The Pharma Data
NOVEMBER 3, 2020
4, 2020 /PRNewswire/ — In its virtual booth at the 2020 Radiological Society of North America (RSNA) annual meeting, international medical imaging IT and cybersecurity company Sectra (STO: SECT B) will showcase its complete enterprise imaging offering, which empowers radiologists to accomplish more. LINKÖPING, Sweden , Nov.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
FEBRUARY 21, 2022
At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.
The Pharma Data
JANUARY 19, 2021
20, 2021 /PRNewswire/ — Serenno Medical , developer of medical devices for patient monitoring in a hospital setting, announced today that Elcam Medical , a leading producer of medical devices, has invested $1.5 The Company develops medical devices for patient monitoring in a hospital setting. YOKNEAM, Israel , Jan.
XTalks
JANUARY 19, 2024
Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.
XTalks
SEPTEMBER 11, 2024
Jansen recently moderated a webinar in which her colleagues at Medpace discussed the evolving women’s health sector, including the historical challenges and emerging trends in clinical development. This includes developing new therapies and improving existing ones for chronic conditions long neglected.
Delveinsight
DECEMBER 29, 2020
Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Billion Myovant/ Pfizer Deal. Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist.
Expert insights. Personalized for you.
94 
Let's personalize your content